To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
69 Current news of UCBrss
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD) and for the symptomatic treatment of moderate-to-severe idiopathic Restless Legs Syndrome (RLS) in adults. In 2002 Otsuka Pharmaceutical ...
Astellas Pharma Inc. and UCB S.A. announced that UCB Japan has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Cimzia® (certolizumab pegol). Cimzia®, under joint development in Japan, has been approved as a 200 mg syringe for subcutaneous ...
Collaboration aims to accelerate drug discovery for new therapies in central nervous system (CNS) disorders and immunology diseases
UCB and Proteros biostructures GmbH announced expansion of their ongoing structural biology collaboration to include additional therapeutic areas. Since 2007, Proteros has supported discovery programmes for UCB in the area of immunology, by solving complex unpublished protein structures to ...
Opening of new pilot biotechnology plant in Belgium
In line with its strategy, and in preparation for the growing demand for biological medicines, UCB inaugurated its new pilot biotechnology plant at its Braine-L’Alleud site in Belgium. UCB’s new biologics pilot production facility was officially opened at a ceremony attended by Jean-Claude ...
Research collaboration launched to develop novel therapies for the treatment of neurodegenerative disease
UCB announced that it has launched a second collaborative research project with Harvard that builds upon the Research Alliance signed between UCB and Harvard in 2011. The second research project comprises a collaboration with the laboratory of Junying Yuan, Ph.D., Professor of Cell Biology at ...
Joins forces with Brazilian Meizler creating Meizler UCB Biopharma S.A.
UCB and Meizler Biopharma, a privately-owned Brazilian pharmaceutical company, announced that they have signed an agreement by which UCB acquires 51% of Meizler Biopharma. The agreement foresees performance related milestone payments in the coming years as well as an option to purchase the ...
UCB announced positive top-line results from the phase 3 study designed to evaluate the efficacy and safety of certolizumab pegol in patients with adult-onset active axial spondyloarthritis (AxSpA), a family of inflammatory rheumatic diseases which includes ankylosing spondylitis (AS)."The ...
First Patient Randomized Marks Start of Phase 3 Program to Evaluate Safety and Efficacy of CDP7851/AMG 785 in Women With Postmenopausal Osteoporosis
UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president of ...
New collaboration to develop research in immunology and neurology
UCB Pharma and Oxford University agreed to collaborate on cutting-edge pharmaceutical research projects, enabling scientists from industry and academia to work together to develop medicines to treat serious diseases in immunology and neurology. These combined resources and expertise will give ...
Combinatorial domain hunting technology aids identification of MEK protein suitable for structure-based drug discovery
UCB and Domainex Ltd have jointly published the results of a collaboration in the field of cancer drug discovery. Working together, the two companies have developed an experimental system to study the three-dimensional structure of Mitogen-activated protein kinase kinase (MAPKK, also known as ...